1.	VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113971, NCT01205230
2.	Adjuvant Pazopanib in Stage I NSCLC Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: IFCT-0703, Eudract : 2008-004897-41, NCT00775307
3.	Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG105192, NCT00334282
4.	Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG107769, NCT00387764
5.	Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 108844, NCT00720941
6.	Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG110727, NCT00753688
7.	Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 110655, NCT00866697
8.	Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113046, NCT01064310
9.	Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SCRI GYN 26, NCT01035658
10.	Pazopanib and Vinflunine in Urothelial Cancer of the Bladder Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: DZITM1, NCT01265940
11.	GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG102616, UCLA-0508053-01, UCLA-0506058-01, GSK-VEG102616, NCT00244764
12.	Phase II Study of GW786034 in Patients With Relapsed or Refractory Advanced or Metastatic Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-62043, GSK-EORTC-62043, EUDRACT-2004-004378-10, NCT00297258
13.	Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma Phase: Phase II Type: Treatment Status: Completed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG20006, NCT00256880
14.	A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 104450, NCT00281632
15.	Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG20007, NCT00347919
16.	Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG102857, NCT00350727
17.	Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG105290, NCT00367679
18.	Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG105281, NCT00430781
19.	Phase II Study of Pazopanib Hydrochloride in Patients With Stage IV or Recurrent Nasopharyngeal Carcinoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CTRG-NP05/25/06, 7623, SINGAPORE-NCC-06-01, NCC-06-01, NCT00454142
20.	Pazopanib in Treating Patients With Recurrent Glioblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02710, NABTC-0602, U01CA062399, CDR0000538083, 737754, NCI-07-C-0138, NCT00459381
21.	Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00202, N01CM62201, CDR0000538086, 14954A, UCCRC-14954A, 7659, NCT00454571
22.	Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00656, N0623, U10CA025224, CDR0000539269, NCCTG-N0623, NCT00459862
23.	Pazopanib in Treating Patients With Metastatic Urothelial Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00203, MC0553, CDR0000543460, N01CM62205, MAYO-MC0553, 7661, NCT00471536
24.	Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00200, PHL-058, PMH-PHL-058, PMH-10036920, CDR0000549528, N01CM00032, 7640, NCT00486642
25.	Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00199, PHL-057, N01CM62203, CDR0000557347, PMH-PHL-057, 7638, NCT00509587